Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China; Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China.
Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China; Medical Research Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510120, China; Guangzhou Regenerative Medicine and Health Guangdong Laboratory, Guangzhou 510005, China; Fountain-Valley Institute for Life Sciences, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou 510530, China.
Trends Cancer. 2022 Jul;8(7):527-555. doi: 10.1016/j.trecan.2022.03.001. Epub 2022 Mar 21.
The view of cancer as a tumor cell-centric disease is now replaced by our understanding of the interconnection and dependency of tumor stroma. Cancer-associated fibroblasts (CAFs), the most abundant stromal cells in the tumor microenvironment (TME), are involved in anticancer therapeutic resistance. As we unearth more solid evidence on the link between CAFs and tumor progression, we gain insight into the role of CAFs in establishing resistance to cancer therapies. Herein, we review the origin, heterogeneity, and function of CAFs, with a focus on how CAF subsets can be used as biomarkers and can contribute to therapeutic resistance in cancer. We also depict current breakthroughs in targeting CAFs to overcome anticancer therapeutic resistance and discuss emerging CAF-targeting modalities.
目前，我们已经不再将癌症视为一种以肿瘤细胞为中心的疾病，而是认识到肿瘤基质的相互联系和相互依存。肿瘤相关成纤维细胞（cancer-associated fibroblasts，CAFs）是肿瘤微环境（tumor microenvironment，TME）中最丰富的基质细胞，它们参与了抗肿瘤治疗的耐药性。随着我们挖掘出更多关于 CAFs 与肿瘤进展之间关联的可靠证据，我们对 CAFs 在建立肿瘤治疗耐药性方面的作用有了更深入的了解。本文综述了 CAFs 的起源、异质性和功能，重点介绍了 CAF 亚群如何用作生物标志物，并有助于癌症治疗耐药性。我们还描绘了靶向 CAFs 以克服抗肿瘤治疗耐药性的当前突破，并讨论了新兴的 CAF 靶向治疗方法。
